Evotec, LLS Enter Strategic Research Pact

Evotec AG has entered into a research collaboration with The Leukemia & Lymphoma Society (LLS) to support one of LLS’s Screen-to-Lead Programs (SLP). Evotec will support selected programs and principal investigators with resources for high-throughput screening and optimization of small molecules into drug-like compounds. Financial details were not disclosed.
 
Dr. Mario Polywka, chief operating officer of Evotec, said, “We are excited to initiate this collaboration and support The Leukemia and Lymphoma Society and their investigators. We are confident that our experienced scientists and innovation platform can deliver results for LLS, their investigators and ultimately patients.”
 
Amy Burd, Ph.D., executive director of research at LLS, added, “LLS is pleased to be working in collaboration with Evotec to advance our Screen-to-Lead programs. We feel that Evotec has the necessary skills and capabilities to offer significant value to support these projects.”